zinc finger protein 37B, pseudogeneGenealiases: []
Q-omics provides the consensus-scored ZNF37BP profile across patient tissues and cancer cell-line models. ZNF37BP expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, ZNF37BP is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, ZNF37BP RNA expression shows 21,421 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LIHC, COAD, and UVM as cancer lineages where ZNF37BP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF37BP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF37BP survival associations across molecular data types. ZNF37BP RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF37BP RNA expression–survival associations across cancer types. High ZNF37BP expression shows unfavorable associations in LIHC, ACC, KIRC and KICH, but favorable associations in PAAD and HNSC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for ZNF37BP RNA expression.
This table summarizes ZNF37BP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF37BP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF37BP shows lower tumor expression in THCA and BRCA and higher tumor expression in COAD, LIHC, HNSC and CHOL. The COAD box plot shows higher ZNF37BP RNA expression in tumor versus normal tissue (log2 FC = +0.796, t-test p < 0.001).
This table shows molecular features associated with ZNF37BP in patient tissues and cancer cell lines. In patient samples, ZNF37BP shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF37BP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in NCI60_ALL.
